Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.08
- Piotroski Score 2.00
- Grade Buy
- Symbol (ALDX)
- Company Aldeyra Therapeutics, Inc.
- Price $4.98
- Changes Percentage (3.53%)
- Change $0.17
- Day Low $4.69
- Day High $4.98
- Year High $6.55
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $12.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.51
- Trailing P/E Ratio -7.57
- Forward P/E Ratio -7.57
- P/E Growth -7.57
- Net Income $-37,542,510
Income Statement
Quarterly
Annual
Latest News of ALDX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory
Aldeyra Therapeutics is a biotech company focusing on innovative treatments for immune disorders like dry eye disease with its lead product, reproxalap. Despite setbacks, strategic partnerships and pi...
By Yahoo! Finance | 2 months ago -
Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
Institutional investors hold a significant 36% stake in Aldeyra Therapeutics, influencing the company's direction. Insider ownership stands at 1.9%, while the general public and private equity firms h...
By Yahoo! Finance | 3 months ago
